Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu
fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment for adults with HER2-positive breast cancer (IHC 3+ or ISH-positive) and residual invasive disease after neoadjuvant trastuzumab with or without pertuzumab and a taxane-based regimen.
LAMPGEN ANALYSIS
Why it matters
DESTINY-Breast05 tested an ADC against T-DM1 in residual disease after neoadjuvant therapy. That post-surgery risk population differs from the newly approved presurgery indication.
What research teams should watch
Reconcile the neoadjuvant regimen with residual invasive disease on surgical pathology. Build a clear process for monitoring and escalating potential ILD or pneumonitis.
PRIMARY RECORDS